Reports Q4 revenue $1.17M, consensus $1.25M. “In 2024, Celldex (CLDX) set a new bar for efficacy in chronic urticarias-presenting best-in-disease data across both our Phase 2 studies in CSU and CIndU,” said Anthony Marucci, co-founder, president and CEO of Celldex Therapeutics. “Our Phase 3 studies in CSU have been met with great enthusiasm from the global medical community and are actively enrolling patients around the world. We look forward to building on this momentum later this year when we initiate our Phase 3 program in CIndU.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex initiated with a Buy at UBS
- Buy Recommendation for Celldex: Barzolvolimab’s Market Leadership and Efficacy Drive Positive Outlook
- Blueprint Medicines price target lowered to $124 from $135 at Wedbush
- Jasper Therapeutics price target lowered to $64 from $90 at BTIG
- JMP Securities healthcare analysts hold an analyst/industry conference call